HPC
HAE icon

HM Payson & Co’s Haemonetics HAE Stock Holding History

HM Payson & Co’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16
Closed -$1K – 1116
2021
Q3 		$1K Hold
16
– – ﹤0.01% 1044
2021
Q2 		$1K Hold
16
– – ﹤0.01% 1050
2021
Q1 		$2K Hold
16
– – ﹤0.01% 1042
2020
Q4 		$2K Buy
+16
New +$1.72K ﹤0.01% 1013
2020
Q1 		– Sell
-166
Closed -$19K – 931
2019
Q4 		$19K Hold
166
– – ﹤0.01% 721
2019
Q3 		$21K Buy
+166
New +$21.1K ﹤0.01% 721

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

HM Payson & Co's HAE Position: Q4 2021 in Review

HM Payson & Co sold out of Haemonetics (HAE) in Q4 2021, closing a stake of 16 shares — an estimated $1K sold.

HM Payson & Co first reported a position in HAE in Q3 2019 and held it in 6 quarters. The position peaked at $21K in Q3 2019. 257 funds tracked by Wall St. Rank hold HAE as of Q4 2021.

  • HM Payson & Co reported no remaining Haemonetics position as of Q4 2021 after selling out during the quarter.
  • HM Payson & Co sold 16 Haemonetics shares in Q4 2021, an estimated $1K.
  • HM Payson & Co first reported a position in Haemonetics in Q3 2019 and held it in 6 quarters.
  • HM Payson & Co's Haemonetics position peaked at $21K in Q3 2019.
  • 257 funds tracked by Wall St. Rank held Haemonetics as of Q4 2021.

Based on HM Payson & Co's 13F filing for Q4 2021, filed 15 Feb 2022.